摘要
无处不在的染色质开放元件从人类HNRPA2B1-CBX3管家基因位点(A2UCOE)能够提供稳定的和细胞的转基因表达的细胞复制水平无论在成人的证明疗效的靶细胞基因组的整合位点,胚胎干细胞和诱导多能干细胞和其分化的子代在体外和体内。在这里,我们评估基于A2UCOE能力赋予稳定表达的慢病毒载体在小鼠出生前交付。我们的研究结果在肝脏与表达中展示高效转导的胎肝和造血干细胞的造血系统伴随持续稳定的产后A2UCOE- EGFP和A2UCOE荧光素酶报告基因的慢病毒载体存在。此外,我们发现一个A2UCOE-fix慢病毒载体产生相当大量的血浆蛋白,确定从sffv-fix获得构建。此外,该A2UCOE-fix矢量显示在低(0.19)平均每肝细胞载体的拷贝数,它可以提供等离子体固定生产稳定的水平,这将严重的血友病B(<1%)到一个温和的表型(≈20%)。我们的研究结果提供了低剂量的产前A2UCOE基于LV运送到肝脏的证据原则作为血友病B和潜在的其他代谢性疾病的一种治疗选择。
关键词: UCOE,Haemophilia B,慢病毒载体,出生前,基因治疗。
Current Gene Therapy
Title:Haemophilia B Curative FIX Production from a Low Dose UCOE-based Lentiviral Vector Following Hepatic Pre-natal Delivery
Volume: 16 Issue: 4
Author(s): Vincent Yu-cheng Kao, Sonia Ferreira, Simon N. Waddington, Michael N. Antoniou
Affiliation:
关键词: UCOE,Haemophilia B,慢病毒载体,出生前,基因治疗。
摘要: The ubiquitous chromatin opening element from the human HNRPA2B1-CBX3 housekeeping gene locus (A2UCOE) is able to provide stable and cell-to-cell reproducible levels of transgene expression regardless of target cell genome integration site with efficacy demonstrated in adult, embryonic and induced pluripotent stem cells and their differentiated progeny in vitro and in vivo. Here we evaluate the ability of A2UCOE-based lentiviral vectors to confer stable expression following pre-natal delivery in mice. Our results show stable post-natal A2UCOE-eGFP and A2UCOE-luciferase lentiviral vector presence in both the liver and haematopoietic system with concomitant persistence of expression demonstrating efficient transduction of both fetal liver and haematopoietic stem cells. In addition, we find that an A2UCOE-FIX lentiviral vector produces comparable amounts of plasma FIX protein to that obtained from a SFFV-FIX construct. Furthermore, the A2UCOE-FIX vector shows that at a low (0.19) average vector copy number per liver cell, it can provide stable levels of plasma FIX production, which would convert severe haemophilia B (<1%) to a mild phenotype (≈20%). Our results provide proof-ofprinciple for low dose pre-natal A2UCOE-based LV delivery to the liver as a therapeutic option for haemophilia B and potentially other metabolic conditions.
Export Options
About this article
Cite this article as:
Vincent Yu-cheng Kao, Sonia Ferreira, Simon N. Waddington, Michael N. Antoniou , Haemophilia B Curative FIX Production from a Low Dose UCOE-based Lentiviral Vector Following Hepatic Pre-natal Delivery, Current Gene Therapy 2016; 16 (4) . https://dx.doi.org/10.2174/1566523216666161102150101
DOI https://dx.doi.org/10.2174/1566523216666161102150101 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements